These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 35276128)
1. Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Joannes A; Morzadec C; Duclos M; Gutierrez FL; Chiforeanu DC; Le Naoures C; De Latour B; Rouzé S; Wollin L; Jouneau S; Vernhet L Toxicol Appl Pharmacol; 2022 Apr; 441():115972. PubMed ID: 35276128 [TBL] [Abstract][Full Text] [Related]
2. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706 [TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Luo F; Zhuang Y; Sides MD; Sanchez CG; Shan B; White ES; Lasky JA Respir Res; 2014 Apr; 15(1):51. PubMed ID: 24762191 [TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effects of vitamin D3 on human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Voisin T; Joannes A; Morzadec C; Lagadic-Gossmann D; Naoures CL; De Latour BR; Rouze S; Jouneau S; Vernhet L J Nutr Biochem; 2024 Mar; 125():109558. PubMed ID: 38185349 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-like 2 (NFE2L2) protein and the Smad2/3 pathway. Zhong L; Hao H; Chen D; Hou Q; Zhu Z; He W; Sun S; Sun M; Li M; Fu X J Cell Physiol; 2019 Mar; 234(3):2606-2617. PubMed ID: 30317545 [TBL] [Abstract][Full Text] [Related]
6. TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression. Huang Y; Xie Y; Abel PW; Wei P; Plowman J; Toews ML; Strah H; Siddique A; Bailey KL; Tu Y Biochem Pharmacol; 2020 Oct; 180():114172. PubMed ID: 32712053 [TBL] [Abstract][Full Text] [Related]
7. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Lambers C; Roth M; Jaksch P; Muraközy G; Tamm M; Klepetko W; Ghanim B; Zhao F Sci Rep; 2018 Jan; 8(1):1087. PubMed ID: 29348469 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Liu M; Zeng X; Wang J; Fu Z; Wang J; Liu M; Ren D; Yu B; Zheng L; Hu X; Shi W; Xu J Stem Cell Res Ther; 2016 Apr; 7(1):63. PubMed ID: 27107963 [TBL] [Abstract][Full Text] [Related]
11. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. Zhang L; Li Y; Liang C; Yang W Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150 [TBL] [Abstract][Full Text] [Related]
12. Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis. Kurumiya E; Iwata M; Kasuya Y; Tatsumi K; Honda T; Murayama T; Nakamura H Eur J Pharmacol; 2024 Mar; 966():176366. PubMed ID: 38296153 [TBL] [Abstract][Full Text] [Related]
13. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015 [TBL] [Abstract][Full Text] [Related]
14. Sphingosine Kinase 1/S1P Signaling Contributes to Pulmonary Fibrosis by Activating Hippo/YAP Pathway and Mitochondrial Reactive Oxygen Species in Lung Fibroblasts. Huang LS; Sudhadevi T; Fu P; Punathil-Kannan PK; Ebenezer DL; Ramchandran R; Putherickal V; Cheresh P; Zhou G; Ha AW; Harijith A; Kamp DW; Natarajan V Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192225 [TBL] [Abstract][Full Text] [Related]
15. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329 [TBL] [Abstract][Full Text] [Related]
16. Dopamine Receptor D1 Is Exempt from Transforming Growth Factor Gao AY; Diaz Espinosa AM; Nguyen BBN; Link PA; Meridew J; Jones DL; Gibbard DF; Tschumperlin DJ; Haak AJ J Pharmacol Exp Ther; 2023 Sep; 386(3):277-287. PubMed ID: 37024146 [TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. Bocchino M; Agnese S; Fagone E; Svegliati S; Grieco D; Vancheri C; Gabrielli A; Sanduzzi A; Avvedimento EV PLoS One; 2010 Nov; 5(11):e14003. PubMed ID: 21103368 [TBL] [Abstract][Full Text] [Related]
18. TGF-β1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. Wygrecka M; Zakrzewicz D; Taborski B; Didiasova M; Kwapiszewska G; Preissner KT; Markart P Am J Respir Cell Mol Biol; 2012 Nov; 47(5):614-27. PubMed ID: 22771387 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts. Dubey S; Dubey PK; Umeshappa CS; Ghebre YT; Krishnamurthy P J Cell Physiol; 2022 Apr; 237(4):2169-2182. PubMed ID: 35048404 [TBL] [Abstract][Full Text] [Related]
20. Autophagy and the unfolded protein response promote profibrotic effects of TGF-β Ghavami S; Yeganeh B; Zeki AA; Shojaei S; Kenyon NJ; Ott S; Samali A; Patterson J; Alizadeh J; Moghadam AR; Dixon IMC; Unruh H; Knight DA; Post M; Klonisch T; Halayko AJ Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L493-L504. PubMed ID: 29074489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]